MedTrace Logo

Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening

NCT00870688 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2009-05-20

Study results available
· View outcomes & findings →

Summary

Valproate is the first line therapy in primary generalized seizures. The applied drug contains sodium valproate in sustained release minitablets. As a multiple unit dosage form these can be easily swallowed and taken independent from meals.

A simple dosage scheme like valproate sustained release minitablets once daily in the evening should improve the compliance and likely the seizure situation of the patients. The data of this non interventional trial were directly extracted from the physician's electronic patient database. The observational period was 7 weeks compared to a retrospective period 7 weeks before start of the study.

Conditions

Interventions

DRUG

sodium valproate

valproate sustained release minitablets, once daily.

Sponsors & Collaborators

  • Desitin Arzneimittel GmbH

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2006-04-30
Completion
2006-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00870688 on ClinicalTrials.gov